The Kinghorn Centre for Clinical Genomics (KCCG) is led by Associate Professor Marcel Dinger and comprises five teams that work closely together.
Since 2012, KCCG grew to more than 60 team members with skills across sequencing, informatics, clinical interpretation, business development, and education. In 2016, Garvan launched its wholly-owned subsidiary, Genome.One to provide genetic answers to health questions through clinical whole genome sequencing and analysis. In 2017, with continued support from the Kinghorn Foundation, KCCG reorganised into five key teams that tackle major challenges that will ultimately enable advance the translation of genomic information to improve health:
|The teams are:|
|Translational Genome Informatics||Genomic Technologies||Population-scale Health Analytics|
|Cancer Genomics||Visiting Scientists|
The Centre Management team is responsible for the broad oversight of KCCG operations and its interaction with with Genome.One. This includes: the management of flagship-sequencing projects initiated through the Sydney Genomics Collaborative; the management and promotion of KCCG sequencing services to both the national and international research community; the development and maintenance of new and on going collaborations and partnerships; and the procurement of external funding for genomic research and infrastructure.
|A/Prof Marcel Dinger||Dr Marie-Jo Brion||Melissa Vincent|
This team has been brought together to advance the state-of-the-art in whole genome interpretation for the clinic. The team develops new tools and algorithms for reliably identifying and classifying noncoding regions of the genome that could directly relate to disease pathogenicity, with the aim of expanding the scope of clinical reporting. This team aims to advance the field of whole genome interpretation and enable translation of this research to Genome.One, so that it has access to the most advanced approaches in clinical interpretation.
|Dr Alexander Drew||Dr Kishore Kumar||Dr Andre Minoche||Clare Puttick|
|Dr Nenad Bartonicek||Dr Lisa Ewans||James Torpy||Mahdi Zeraati|
|Dr Madhura Bakshi||Dr Amali Mallawaarachchi||Beth Signal||Dr Brian Gloss|
This team is responsible for evaluating new genomics technologies for both clinical and research applications and, where appropriate, establish a pathway for translation of new technologies and techniques into Genome.One.
|Dr Martin Smith||James Ferguson||Kirston Barton||
This team, led by Dr Tudor Groza and Dr Warren Kaplan focuses on devising computational approaches to infer actionable knowledge from large-scale genotype – phenotype associations. Particular topics will include population statistical genomics, text/data mining and Machine Learning from EHRs, building temporal disease models from the genome – phenome – exposome triumvirate. The aim is to provide an analytical framework to cover the diagnosis – prevention continuum for improved clinical and patient care.
|Dr Tudor Groza||Dr Warren Kaplan||Dmitry Degrave||Shane Husson|
|Dr Simon Kocbek||Derrick Lin||Dr Frank Lin||Manuel Sopena-Ballesteros|
The KCCG Cancer Genomics team develops approaches to analyse and interpret cancer genome data, predominantly for patients with rare and advanced cancers. The team has a strong focus on translational research, and as such develops approaches to enable fast, accurate analysis and interpretation of individual tumour genomes. The team works closely with the Garvan Genomic Cancer Medicine program and leads the genomic analyses of the Molecular Stratified Therapeutics Trial (MoST), and the Lions Kids Cancer Genome Project (LKCGP). This is complemented by research focussed on tumour evolution, noninvasive monitoring, and understanding the drivers of rare cancers.
|Dr Mark Cowley||Dr Mark McCabe||Dr Marie Wong||Dr Velimir Gayevskiy|
|Dr John Grady||Dr Nisa Sheriff||Chia-Ling Chan|
Our education and communication program, led by Bronwyn Terrill, focuses on engaging health care professionals and the diverse communities that make up our population with the complex and fast-moving field of genomics.
|Bronwyn Terrill||Krista Recsei||Andrew Gibb|
The impact of clinical genomics is becoming widespread and its importance to diverse disciplines is becoming increasingly recognised. KCCG engages closely with scientists, clinicians and ethicists through visiting appointments. These individuals bring additional expertise to KCCG and provide a mechanism for reciprocal engagement into the broader genomics community.
|Prof Andreas Zankl||Dr Jacqueline Savard||Dr Paul Lacaze||
|Dr Elizabeth (Emma) Palmer||Prof Carolyn Sue||Dr Ryan Davis||Peter Priestley|